This Article Full Text Full Text (PDF) HTML Page - index.htslp All Versions of this Article: 119/6/845    most recent CIRCULATIONAHA.108.816454v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lähteenvuo, J. E. Articles by Ylä-Herttuala, S. Search for Related Content PubMed PubMed Citation Articles by Lähteenvuo, J. E. Articles by Ylä-Herttuala, S. Pubmed/NCBI databases Substance via MeSH Related Collections Biochemistry and metabolism Angiogenesis Animal models of human disease Apoptosis Growth factors/cytokines Echocardiography Acute myocardial infarction Gene therapy Endothelium/vascular type/nitric oxide Related Article

(Circulation. 2009;119:845-856.)
© 2009 American Heart Association, Inc.

Molecular Cardiology

Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1– and Neuropilin Receptor-1–Dependent Mechanisms

Johanna E. Lähteenvuo, MD; Markku T. Lähteenvuo, MD; Antti Kivelä, MD; Carolina Rosenlew, MSc; Annelie Falkevall, PhD; Joakim Klar, PhD; Tommi Heikura, MSc; Tuomas T. Rissanen, MD, PhD; Elisa Vähäkangas, MD; Petra Korpisalo, MD; Berndt Enholm, MD, PhD; Peter Carmeliet, MD, PhD; Kari Alitalo, MD, PhD; Ulf Eriksson, PhD; Seppo Ylä-Herttuala, MD, PhD, FESC

From the Department of Biotechnology and Molecular Medicine (J.E.L., M.T.L., A.K., T.H., T.T.R., E.V., P.K., S.Y.-H.), A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland; Ludwig Institute for Cancer Research Ltd, Karolinska Institutet (C.R., A.F., J.K., U.E.), Stockholm, Sweden; Molecular and Cancer Biology Laboratory (B.E., K.A.), Haartman Institute, University of Helsinki, Helsinki, Finland; and Flanders Interuniversity Institute for Biotechnology (P.C.), Katholieke Universiteit Leuven, Leuven, Belgium.

Reprint requests to Seppo Ylä-Herttuala, MD, PhD, FESC, Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland. E-mail Seppo.Ylaherttuala{at}uku.fi

Received December 5, 2007; accepted December 9, 2008.

Background— New revascularization therapies are urgently needed for patients with severe coronary heart disease who lack conventional treatment options.

Methods and Results— We describe a new proangiogenic approach for these no-option patients using adenoviral (Ad) intramyocardial vascular endothelial growth factor (VEGF)-B₁₈₆ gene transfer, which induces myocardium-specific angiogenesis and arteriogenesis in pigs and rabbits. After acute infarction, AdVEGF-B₁₈₆ increased blood vessel area, perfusion, ejection fraction, and collateral artery formation and induced changes toward an ischemia-resistant myocardial phenotype. Soluble VEGF receptor-1 and soluble neuropilin receptor-1 reduced the effects of AdVEGF-B₁₈₆, whereas neither soluble VEGF receptor-2 nor inhibition of nitric oxide production had this result. The effects of AdVEGF-B₁₈₆ involved activation of neuropilin receptor-1, which is highly expressed in the myocardium, via recruitment of G-protein- interacting protein, terminus C (GIPC) and upregulation of G-protein- interacting protein. AdVEGF-B₁₈₆ also induced an antiapoptotic gene expression profile in cardiomyocytes and had metabolic effects by inducing expression of fatty acid transport protein-4 and lipid and glycogen accumulation in the myocardium.

Conclusions— VEGF-B₁₈₆ displayed strikingly distinct effects compared with other VEGFs. These effects may be mediated at least in part via a G-protein signaling pathway. Tissue-specificity, high efficiency in ischemic myocardium, and induction of arteriogenesis and antiapoptotic and metabolic effects make AdVEGF-B₁₈₆ a promising candidate for the treatment of myocardial ischemia.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2009 119: 765-767. [Extract] [Full Text]